Zachary Bloomgarden, MD: Onglyza (saxagliptin) launch
August 5, 2009
The Bristol-Meyers Squibb drug Onglyza was recently approved by the FDA and is crucial for the company as a replacement for lost patented drugs. Plavix soon loses patent protection as well. We interviewed clinical diabetes expert and Editor of The Journal of Diabetes, Dr. Bloomgarden, about the DPP4-inhibiotr class, which included Januvia, and whether Onglyza has a better efficacy or safety profile than Januvia.
Diabetes, Endocrinology, Internal medicine, Mt Sinai NYC | apples49 | 
January 6, 2010 1:45 am
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
TrackBack URI
